Strona 4 - Najlepsi lekarze do leczenia raka trzustki – TOP 130 lekarzy

Docent Tahsin Ozatli specjalizuje się w leczeniu raka piersi, płuc oraz nowotworów układu pokarmowego w Szpitalu Uniwersyteckim Istinye Liv.

• Posiada doświadczenie zdobyte w wielu klinikach onkologicznych, w tym w szpitalach państwowych i badawczych
• Uzyskał tytuł docenta w 2016 roku
• Studiował medycynę na Uniwersytecie Selcuk w Konya, Turcja

Specjalizując się w wiroterapii — jednej z najnowszych dziedzin immunologii — dr Jaunalksne wnosi ponad 30-letnie doświadczenie w leczeniu raka trzustki.

• Kieruje Centrum Immunologii Klinicznej w Szpitalu Uniwersyteckim im. Paulsa Stradiņša
• Absolwentka Ryskiego Instytutu Medycznego, ukończyła staż podyplomowy w zakresie chorób wewnętrznych
• Skupia się na innowacyjnych podejściach immunologicznych w leczeniu nowotworów

Profesor Gul Alco specjalizuje się w onkologii radioterapeutycznej raka trzustki na Uniwersytecie Medipol w Stambule.

• Posiada ponad 20-letnie doświadczenie w onkologii radioterapeutycznej
• Specjalizuje się w leczeniu raka trzustki
• Pracowała jako docent, a następnie profesor na Uniwersytecie Demiroglu Bilim
• Odbyła liczne szkolenia w zakresie onkologii radioterapeutycznej

Ukończył zaawansowane szkolenie w zakresie chirurgii laparoskopowej i bariatrycznej na Uniwersytecie Stambulskim. Jest liderem w stosowaniu małoinwazyjnych technik leczenia raka trzustki.

• Specjalizuje się w chirurgii laparoskopowej od 2002 roku
• Odbył zaawansowane szkolenie w zakresie laparoskopowej chirurgii bariatrycznej oraz onkologicznej
• Uzyskał wykształcenie w czołowych tureckich instytucjach medycznych, w tym na Uniwersytecie Stambulskim

Doc. dr Nail Paksoy specjalizuje się w leczeniu raka trzustki w szpitalu Medipol Bahçelievler. Jego praca opiera się na bogatym doświadczeniu badawczym i klinicznym.

• Posiada certyfikat ESMO w dziedzinie onkologii klinicznej
• Współbadacz w badaniach klinicznych nad rakiem trzustki, w tym RECITE – AMGEN
• Autor publikacji naukowych dotyczących porównania metod FOLFIRINOX oraz Gemcytabina + Nab-paklitaksel w leczeniu raka trzustki
• Odbył staż specjalistyczny w Instytucie Onkologii Uniwersytetu Stambulskiego

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr Auala Hubert kieruje Centrum Onkologii Układu Pokarmowego w Centrum Medycznym Hadassah. Jest liderem specjalizującym się w leczeniu nowotworów układu trawiennego, w tym raka trzustki.

• Posiada 33-letnie doświadczenie specjalistyczne w onkologii i radioterapii.
• Stoi na czele dedykowanego multidyscyplinarnego centrum onkologii w czołowym szpitalu uniwersyteckim.
• Posiada certyfikację zarówno w dziedzinie onkologii klinicznej, jak i radioterapii.
• Jest aktywnym członkiem krajowego komitetu ds. nowotworów układu pokarmowego.
• Posiada dyplomy z zakresu medycyny i psychologii.

Prof. Dr. Önder SÜRGİT is a General Surgeon in the General Surgery Clinic. Working hours: 09:00–18:00. Core practice areas include laparoscopic surgery, cancer surgery, and bariatric surgery.

Graduated from Hacettepe Faculty of Medicine in 1995. Academic title: Professor. Served as Instructor Surgeon at ITEM (Advanced Medical Technologies Training Center). Held faculty roles at Turgut Özal University and Atılım University, Faculties of Medicine. Also worked at Ankara Medicana Hospital and Optimed Health Group. Foreign language: English.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Dr Ozden posiada ponad 20-letnie doświadczenie medyczne i specjalizuje się w leczeniu raka trzustki w szpitalu VM Medical Park Pendik.

• Ukończył prestiżowy Wydział Medyczny Cerrahpaşa na Uniwersytecie Stambulskim
• Ukończył podspecjalizację z onkologii klinicznej na Uniwersytecie Kocaeli
• Posiada bogate doświadczenie w zakresie chorób wewnętrznych zdobyte przed specjalizacją onkologiczną

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Specjalizuje się w chirurgii raka trzustki w szpitalach Büyük Anadolu, koncentrując się na złożonych procedurach onkologicznych.

• Ekspert w zakresie chirurgii raka trzustki, dróg żółciowych i żołądka
• Wykonuje zaawansowane operacje onkologiczne oraz bariatryczne operacje metaboliczne
• Specjalizuje się w małoinwazyjnych technikach leczenia nowotworów

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.